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eIF4Gcer factor (NRSF) functions as a transcriptional repressor of neuronal genes in
nonneuronal cells. However, it is expressed in certain mature neurons in adults, suggesting that it might have
complex and novel roles depending on its cellular and physiological context. Overexpression of NRSF led to
both increased opioid ligand-binding activity of the endogenousMOR andMOR–GFP fusionprotein expression.
In RNA immunoprecipitation and gel-shift assays, NRSF speciﬁcally interactedwith the NRSE sequence ofMOR
mRNA. When MOR and NRSF genes were coexpressed, the speciﬁc ligand-binding activity of MOR was
increased in neuroblastoma NMB cells, but decreased in PC12 cells result from its localization. Indeed, after
overexpressing NRSF in NMB cells, the target RNA moved to the translationally active polysomal fraction.
Overexpression of NRSF also led to enhanced phosphorylation of eIF4G. In contrast, knockdown of NRSF by
siRNA transfection signiﬁcantly decreased eIF4G phosphorylation. These ﬁndings indicate that NRSF may
deliver the targetMOR transcripts to the polyribosomal complex and activate eIF4G phosphorylation, resulting
in translational activation. We report here a novel function of NRSF that enhance the translation of the mu
opioid receptor (MOR) gene through its RNA binding sequence, the neuron-restrictive silencer element (NRSE).
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe mu opioid receptor (MOR) is a member of the superfamily of G
protein-coupled receptors and is activated by opioids and endogenous
opioid peptides. Based largely on pharmacological and clinical studies,
theMORhas traditionally been considered themain site of interaction of
major clinically used analgesics, particularly morphine [1]. Morphine
and its relatedopioiddrugs are best known for their analgesic effects and
potential for abuse. Besides itsmajor role in the action of opioid drugs (as
determined mainly by studies on MOR knockout mice), this receptor is
also required for nicotine-induced antinociception and rewardingeffects
of nicotine [2]. These actions are initiated through cell-surface opioid
receptors that contain seven transmembrane domains and are coupled
to G-proteins that mediate opioid actions such as inhibition of adenyl
cyclase and regulation of ion channels. Thus, the regulation of MOR
expression, particularly with regard to the spatial and temporal
expression in the brain, is a major area of research aimed at under-
standing the response of various agents.
Our laboratory has studied several cis-acting elements and their
regulatory factors in the MOR promoter region [3–16]. The neuron-ogy and The Second Stage of
-dong, Dong-gu, Gwangju 501-
3 3205.
l rights reserved.restrictive silencer factor (NRSF) is a major transcriptional repressor of
the MOR promoter that has a critical role in the regulation of the MOR
gene and a synergic repression effect through its interaction with the
Sp3 transcription factor [10,11]. NRSF was originally identiﬁed as a
transcriptional repressor that silenced the neuronal gene in non-
neuronal cells. It also acts as a tumor repressor in colon cancer cells
[17,18], suggesting that NRSF is involved in the signaling pathway in
cancer cells and might have a novel function besides transcriptional
regulation. Several previous studies implied that the NRSF/NRSE
(neuron-restrictive silencer element) complex might have a dual
function as a repressor or enhancer, depending on the temporal and
spatial context of its expression but provided no solid evidence [19–
22]. Recent studies reported that NRSF is expressed in neuronal cells
and mature neurons as well as in nonneuronal cells [23], but its
function in these cells remains unknown. However, it is well
established that the human genome contains a smaller number of
genes than expected. The complexity found in higher organisms can
be explained if proteins are multifunctional. Indeed, recent studies
continue to reveal proteins that are capable of a broad repertoire of
functions [18,24]. A recent report indicated that the Emx2 homeogene
transcription factor is expressed at the mRNA and protein levels in
both the nuclear and axonal compartments of olfactory mucosa axon
bundles and in axon terminals. Emx2 could interact with the
eukaryotic translation initiation factor eIF4E, suggesting a role in
1836 C.S. Kim et al. / Biochimica et Biophysica Acta 1783 (2008) 1835–1846translational regulation [24]. TFII-I, which belongs to a family of
general transcription factors, is also expressed in both the nucleus and
cytoplasm and is involved in signal pathways [25]. In this study, wereport that NRSF is present both in and outside of the nucleus
depending on the cell type, and that NRSF locates in the polysomal
fraction with its target mRNA for translational enhancement. The
1837C.S. Kim et al. / Biochimica et Biophysica Acta 1783 (2008) 1835–1846interaction of NRSF with mRNA accompanies the activation of eIF4G
phosphorylation, suggesting a novel function of NRSF in posttran-
scriptional regulation.2. Materials and methods
2.1. Cell culture
Human neuroblastoma NMB and SHSY5Y cells were grown in RPMI
1640 medium supplemented with 10% heat-inactivated fetal bovine
serum (Invitrogen) at 37 °C in a humidiﬁed atmosphere of 5% CO2.
PC12 cells were cultured in 10% CO2 in DMEM with 10% donor horse
serum and 5% fetal bovine serum.
For primary neurons culture, a 25-mm glass coverslip (thickness,
0.08 mm) was glued to the bottom of a 35-mm culture dish with a 22-
mm hole using silicone sealant as previously described [26].
Dissociated neuronal cultures from rat hippocampus at postnatal day
1–2 were prepared as previously described [26,27]. The same method
was used to make dissociated neurons from mouse hippocampus. All
rat studieswere approvedbyUniversity ofMinnesota IACUC and were
performed in accordance with institutional and federal guidelines.
Neurons were plated onto prepared 35-mm culture dishes at a
density of 1×106 cells per dish. The age of cultured neurons was
counted from the day of plating, 1 day in vitro (DIV). The neurons
5–7 DIV were transfected with mycNRSF plasmids.
2.2. Reporter gene constructs
The pmNRSE450 preconstruct was generated by ligation of the
pNRSE vector (−450 to +12) [10] and double-strand oligomers
containing an NcoI site at both the 3′ and 5′ ends digested with NcoI
enzyme (sense oligomer: 5′-TTCAGAACCATGGTTTTGCAGCGCGCC-
GGCCATGGATTCTTC-3′; antisense oligomer: 5′-GAAGAATCCATGGCC-
GGCGCGCTGCAAAACCATGGTTCTGAA-3′). The pmNRSE450 construct
was generated twice by PCR site-directed mutagenesis according to the
manufacturer's protocol (Quikchange™, Stratagene). In vitro mutagen-
esis was carried out on theMORpromoter linked to a luciferase reporter
gene using the following primers (the mutated nucleotides are under-
lined): pmNRSE450-1 (ﬁrst primers), 5′-GAGTCCGCAGCAAGCATTTC-
GAACCATGGA-3′ and 5′-TCCATGGTTCGAAATGCTTGCTGCGGACTC-3′;
pmNRSE450-2 (second primers), 5′-GAGTCCGCAGCAAGCATTTCTCAC-
CATGGA-3′ and 5′-TCCATGGTGAGAAATGCTTGCTGCGGACTC-3′. Finally,
pNRSE450 (−450 to +12, with the translation start site designated as +1)
and pmNRSE450 were generated by PCR site-directed mutagenesis. The
luciferase start codon was mutated using high ﬁdelity Pfu DNA
polymerase according to the manufacturer's protocol (Quikchange™,
Stratagene).
pMORGFP300 construct was cloned to the GFP-N1 vector with the
mouse MOR UTR (−300 to +1) and MOR coding regions (exon 1 to
exon 4).
For in vitro transcription, pNRSE300sp6 and pmNRSE300sp6
constructs were generated by digesting pNRSE300 (−300 to +12,
wild-type NRSE sequence) or pmNRSE300 (−300 to +12, mutated
NRSE sequence) with HindIII and ligation to double-strand sp6
promoter oligomers (containing HindIII sites at both the 3′ and 5′Fig.1.Dual function of NRSF for mu opioid receptor regulation. (A) Expression of MOR–GFP fu
in NMB cells. The MOR–GFP fusion plasmid of pMORGFP300 was cotransfected with either m
cell lysate was subjected to the following western blot with anti-GFP antibody. (B) Western
myc-tagged NRSF expression vector. Protein extracts from cells were probed with c-myc a
transfection of the NRSF expression plasmid in SHSY5Yand NMB cells. All values are the mean
SHSY5Yand NMB cells transiently transfected with myc-tagged NRSF expression plasmid was
compared with vector plasmid samples, which were assigned a value of 1. All values are the
generated by the threshold cycle (Ct) against the logarithmic values of standard DNA plasmends). These were subsequently digested with BamHI and NarI and
ligated to the uAUG(+) [28] construct.
2.3. Transient transfection and reporter gene assay
For luciferase assays, 1×106 cells/well were cultured overnight
before transfection. Equimolar concentrations of various reporter
constructs were transfected using the Effectene transfection reagent
(Qiagen; Valencia, CA), as described previously [10]. For all assays,
pCH110 (β-galactosidase; Amersham Bioscience Inc., Piscataway, NJ)
was cotransfected and measured to normalize transfection efﬁciency.
The luciferase and β-galactosidase activities were determined
according to the manufacturer's instructions (Promega and Tropics;
Madison, WI).
2.4. Reverse transcription-PCR and real-time quantitative PCR analysis
Total RNA was isolated according to the supplier's protocol (TRI
Reagent; Molecular Research Center, Inc.). For reverse transcription-
PCR (RT-PCR), 2 µg of total RNA was reverse transcribed and PCR
was carried out with MOR-speciﬁc primers in the same tube using a
one-step RT-PCR reagent (Qiagen) in a GeneAmp 9600 PCR machine
(Perkin-Elmer). The PCR cycle conditions for MOR (28 cycles for
SHSY5Y cells, 33 cycles for NMB cells) consisted of 95 °C for 45 s,
60 °C for 45 s, and 72 °C for 45 s, followed by a 10-minute
extension at 72 °C. PCR products were separated in a 2.0% agarose
gel with Tris–borate–EDTA buffer. The human MOR transcript was
ampliﬁed with primer set hmor-s (5′-GATCATGGCCCTCTACTCCA-3′,
located at position 216 in exon 1, GenBank number: AY521028) and
TM2as (5′-GCATTTCGGGGAGTACGGAA-3′, located at position 557 in
exon 2). Similar reactions were carried out using primers for β-actin
(sense: 5′-AAGAGAGGCATCCTCACCCT-3′; antisense: 5′-TACAT-
GGCTGGGGTGTTGAA-3′) as an internal control. PCR products sizes
are 360 bp and 217 bp for MOR and β-actin, respectively.
Quantitative analyses were done using ImageQuant 5.2 software
(Amersham).
For real-time quantitative PCR (RT-qPCR), 2 µg of DNase I-treated
RNA were subjected to reverse transcription (Roche) using oligo(dT)
primers. One-fortieth of this reaction was used for real-time PCR
analysis using SYBR Green I dye chemistry. PCR product accumulation
was monitored using an iCycler iQ Real-Time detection system
(Biorad). The mean cycle threshold value (Ct) from triplicate samples
was used to calculate gene expression level. PCR products were
normalized to levels of β-actin. Relative gene expression levels were
determined as described in the User's resource guide from Biorad. To
calculate relative mRNA gene expression, a standard curve was
constructed from ampliﬁcation curves of standard samples containing
101 to 108 molecules of the gene of interest (e.g., the MOR expression
plasmid pmMuEG [8], constructed in our laboratory); the number of
target molecules in the curve from the test sample was determined
from the standard curve. The number of target molecule was
normalized against that obtained for β-actin, used as an internal
control. The speciﬁcities of RT-PCR primers were determined using a
melting curve after the ampliﬁcation to show that only a single species
of RT-qPCR product resulted from the reaction. Single PCR products
were also veriﬁed on an agarose gel.sion protein is enhanced by transient transfection of myc-tagged NRSF expression vector
yc-tagged NRSF expression vector or only vector were cotransfected to NMB cells. The
blot analyses of NRSF expression in SHSY5Y and NMB cells transiently transfected with
ntibody. (C) Endogenous MOR receptor binding is increased signiﬁcantly by transient
±S.E.M. ⁎pb0.05 versusmock vector transfection. (D) Quantiﬁcation of transcripts from
performed by RT-qPCR. Changes in transcript levels for NRSF-transfected samples were
mean±S.E.M. ⁎pb0.05 versus mock vector transfection. (E) The standard curves were
id number.
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Capped and uncapped mRNAs were synthesized in vitro with the
MAXIscript In vitro Transcription Kit (Ambion) according to the
manufacturer's instructions. Brieﬂy, the DNA was transcribed in vitro
by SP6 RNA polymerase in the presence (capped) or absence
(uncapped) of the methylated cap analog m7GpppG (1 mM; Ambion).
After a 1-hour incubation at 37 °C, the sample was treated with DNase
(2 U) for 15 min at 37 °C. After ethanol precipitation and washing with
70% ethanol, the RNA was resuspended in DEPC-treated water. RNA
integrity was conﬁrmed by gel electrophoresis. The amounts of RNA
were analyzed by spectrophotometry and ethidium bromide
visualization.
In vitro translation was performed in 40 µl of reaction mixture
containing 26.4 µl of rabbit reticulocyte lysates (RRL; Promega), 2 µl
of [35S]-methionine, 80 mM KCl, 150 µM MgOAc, 500 ng RNA.
To this mix, either 0.5 µl of in vitro-translated NRSF or same
amount of RRL (as a control) was added. The reaction was
incubated at 30 °C for 30 min, and measured the luciferase
activity according to the manufacturer's instructions (Promega and
Tropics; Madison, WI).
2.6. RNA transfection
After 24 h of transfection with the mycNRSF expression plasmid
(kindly provided by Dr. Avtar Roopra) [29], in vitro-transcribed MOR/
luciferase mRNA was transfected into NMB cells using the TransMes-
senger transfection reagent (Qiagen). After 4 h of incubation at 37 °C in
5% CO2, the mediumwas replaced with normal growing medium. The
cells were incubated an additional 20 h and then harvested in 200 µl
1× Reporter Lysis Buffer (Promega).
2.7. RNA gel-shift assay and RNA immunoprecipitation
In vitro-translated [35S]-labeled NRSF protein was produced from
mycNRSF plasmid and SOX21 expression plasmid (as negative control)
using the TnT Quick-coupled Transcription/Translation System (Pro-
mega). The product was analyzed on an 8% SDS-polyacrylamide gel
electrophoresed for 2 h at 200 V, room temperature. Binding reactions
were performed in 20 µl of 50 mM Tris–HCl (pH 8.2), 10 mM MgCl2,
1 mM EDTA, 10% glycerol, 200 ng of yeast tRNA (Sigma), and 2 U of
RNase inhibitor (Ambion) at 25 °C for 30 min. For supershift
experiments, 1 µl of either monoclonal myc antibody (sc-40, Santa
Cruz Biotechnology) or nonspeciﬁc antibody was added, and the
reactionwas incubated for another 30 min at room temperature. After
the binding reaction, the samples were analyzed by nondenaturing
PAGE performed on a 4% gel in Tris–borate–EDTA buffer at 200 V for
2 h in a cold room. The gels were dried, exposed, analyzed in a
Phosphorimager, and quantiﬁed using ImageQuant version 1.2
(Amersham). For competition experiments, unlabeled competitors
were added to the binding reaction simultaneously with the RNA
probe. Single-stranded RNA oligonucleotides containing a copy of the
MOR NRSE (5′-CAGCAAGCAUUCAGAACCAUGGACAGCAGCGCCGGCC-
CAGGG-3′ and PU.1 (5′-UGAAAUAACCUCUGAAAGAGGAACUUG-
GUUAGGTA-3′) were used for gel-shift assay.
For RNA immunoprecipitation studies, NMB cells were harvested
in lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES [pH 7.0],
0.5% Nonidet P-40, 1 mM DTT, 100 U/ml RNasin ribonuclease
inhibitor [Promega], 2 mM vanadyl ribonucleoside complexesFig. 2.MOR binding activity is enhanced by NRSF expression and the location of the NRSF pro
MOR expression plasmid and control or NRSF expression vector. All values correspond tomea
vector transfection. (B) Immunoﬂuorescent staining of NRSF in PC12, NMB and hippocampa
localization of NRSF was analyzed with anti-myc antibody (green) as well as DAPI nuclear
transfected with mycNRSF expression vector. N: nuclear fraction; C: cytoplasmic fraction. The
(C).solution [BioChemica; Melbourne, FL], 25 µl/ml Protease Inhibitor
Mixture for Mammalian Tissues [Sigma]). Lysate, handled at 4 °C,
was centrifuged at 16,000 g for 15 min, precleared twice for 1 h
with Protein A-agarose (Invitrogen). Mouse monoclonal antibodies
against c-myc (sc-40, Santa Cruz Biotechnology) were added at a
concentration of 10 µg/ml of lysate (~1 mg of protein). One aliquot
of cellular lysate from which the antibody was omitted was
processed through the protocol as a control for nonspeciﬁc binding
to protein A-agarose beads. Samples were rotated overnight at 4 °C.
Protein A-agarose beads (50 µl) were added to each sample and
rotated for 4 h at 4 °C. The beads were pelleted and washed four
times with 0.5 ml of lysis buffer (5 min each), followed by another
four washes with lysis buffer containing 1 M urea. The beads were
resuspended in 100 µl of lysis buffer containing 0.1% SDS and 30 µg
of proteinase K and incubated at 50 °C for 30 min, followed by
phenol:chloroform extraction and ethanol precipitation. The pellet
was resuspended in 10 µl of DEPC water and 4 µl of RNA was used
for RT-PCR using a one-step RT-PCR kit (Qiagen). PCR was done with
30 pmol of primers for 30 cycles. Primers for human mu opioid
receptor were as follows: For MOR1: 5′-TAAGAAACAGCAGGAG-
CTGTGGCA-3′ (188-bp, sense), 5′-GTGCTGGGGAGCAACTTGAG-3′
(188-bp, antisense); For MOR2: 5′-CAGCTCGGTCCCCTCCGCCTGA-3′
(730-bp, sense), 5′-GCATTTCGGGGAGTACGGAA-3′ (730-bp,
antisense).
2.8. Radioligand binding
Binding activity assays were carried out as described previously
[30]. Brieﬂy, after transient transfection with the indicated constructs,
conﬁrmation of MOR expression was determined by a whole-cell
binding assay using [3H]-diprenorphine in 25mMHEPES, 5mMMgCl2
(pH 7.6). Speciﬁc binding was deﬁned as the difference in the
radioactivity bound to the cells in the presence and absence of
100 mM CTOP.
2.9. Nucleus and cytosol fraction and western blot analysis
Cells from subconﬂuent cultures were washed and scraped into
phosphate-buffered saline and pelleted by centrifugation. For nuclear
and cytosol extracts, cells were lysed in NE-PER extraction reagent
(Pierce) according to the manufacturer's protocol.
For western blot analysis, cells were washed twicewith PBS at 4 °C,
and 0.1 ml of lysis buffer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl,
0.25% sodium deoxycholate, 0.1% Nonidet P-40, 0.1% Triton X-100,
50 mM NaF, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl
ﬂuoride, 50 mM sodium pyrophosphate, 10 mM sodium vanadate and
1× protease inhibitor cocktail (Roche; Indianapolis, IN) was added.
After centrifugation, the supernatant was transferred to a new tube
and SDS-PAGE sample buffer was added to the supernatant.
Approximately 30 µg of protein from each lysate was resolved by
SDS-PAGE and transferred to a polyvinylidene diﬂuride membrane for
immunoblotting. Membranes were blocked 1 h with 10% milk,
followed by incubation for 1 h with primary antibodies against each
of following: anti-c-myc (sc-40, Santa Cruz Biotechnology), anti-β-
actin (sc-47778, Santa Cruz Biotechnology), anti-NRSF (07-579,
Upstate Biotechnology), anti-HDAC1 (06-720, Upstate Biotechnology),
anti-eIF4G (#2498, Cell Signaling Technology) and anti-phospho-
eIF4G (#2441, Cell Signaling Technology). After washing 3 times with
TTBS (0.1% Tween 20, 50 mM Tris–HCl [pH 7.4], 150 mM NaCl),tein. (A) Radioligand binding assay performed on PC12 and NMB cells cotransfected with
n±S.E.M. calculated from at least three independent experiments. ⁎pb0.05 versus mock
l primary neurons (P.N.) transfected with mycNRSF expression vector. The intracellular
staining (blue). (C) Western blot analyses of NRSF localization in PC12 and NMB cells
anti-HDAC1was used for protein purity control. (D) Quantitative analyses of the blots in
Fig. 3. Overexpression of NRSF enhances luciferase activity. Plasmid constructs
(pNRSE450 or pmNRSE450) were each transiently cotransfected with control vector
or myc-tagged NRSF expression plasmid. (A) Schematic representation of the reporter
gene constructs used for transient transfections with the MOR. NRSE (pNRSE450) or
mutant NRSE (pmNRSE450) were cloned into the multiple cloning site of the
pGL3control luciferase reporter vector. (B) Total RNA was extracted from transfected
cells and transcripts were quantiﬁed by RT-qPCR. (C) The promoter activity of each
construct is expressed as relative luciferase activity. Transfection efﬁciencies were
normalized against β-galactosidase activity by cotransfection of pCH110 as an internal
control. All values correspond to mean±S.E.M. calculated from at least three
independent experiments. ⁎pb0.05 versus mock vector transfection.
1840 C.S. Kim et al. / Biochimica et Biophysica Acta 1783 (2008) 1835–1846secondary antibodies conjugated with alkaline phosphate were
added. The membranes were incubated for 1 h and then washed
3 times with TTBS. After developing, the ﬂuorescence intensity of
each band was measured with Storm 860. The intensity of
individual bands was determined with ImageQuant analysis soft-
ware (Amersham).
2.10. Immunoﬂuorescence
PC12, NMB and primary neurons transfected for 24 h with myc-
tagged NRSF expression vector were ﬁxed in 4% formaldehyde. Fixed
cells were washed three times with PBS and blocked in Tris-buffered
saline (TBS)-TM (20 mM Tris–HCl [pH 7.6], 137 mM NaCl, 0.1% Tween
20, 5% skim milk). Cells were incubated with anti-c-myc primary
antibody at 25 °C for 1 h and then washed three times, followed by
incubationwith AlexaFluor 488-linked IgG (Molecular Probes) in TBS-
TM. Cells were counterstained with 4′, 6-diamidino-2-phenylindole
(DAPI) in PBS for 10 min and then washed with PBS. Coverslips were
mountedwith Vectashield H-1000 (Vector Laboratories). Fluorescence
was observed using a Nikon E600 epiﬂuorescence microscope
(Melville, NY, USA).
2.11. siRNA knockdown experiments
NRSF small interfering RNA (siRNA) was purchased from Ambion
(Silencer Predesigned siRNA; #115695 and #115696). Scrambled
(scb) siRNAs (sc-37007) were purchased from Santa Cruz. siRNAs
were transfected into NMB cells using Lipofectamine 2000 transfec-
tion reagent (Invitrogen) according to the supplier's protocol. The
concentrations of siRNAs were optimized to 50 pmol/transfection in
six-well plates with an NMB cell density of 105 per well. Twenty-
four hours after the transfection, proteins were prepared using RIPA
lysis buffer. Western blots were also performed as described
previously.
2.12. Polyribosome fractionations
Polysome fractionation was conducted as described previously
[31]. In brief, NMB cells were cotransfected with pNRSE450 or
pmNRSE450 and either vector or mycNRSF plasmid. The cells were
resuspended in a polysomal buffer containing 10 mM Mops (pH 7.2),
250 mM NaCl, 2.5 mM MgOAc, 0.5% Nonidet P-40, 0.1 mM phenyl-
methylsulfonylﬂuoride, 200 mg/ml heparin, and 50 mg/ml cyclohex-
imide. The polysomes were pelleted by ultracentrifugation at
100,000 g for 1 h at 4 °C. For polysome RNA extraction, the pellet
was used for RNA isolation using TRI reagent according to the
supplier's protocol (Molecular Research Center) and RT-PCR or real-
time PCR were performed.
2.13. Statistical analysis of results
All experiments were performed in triplicate with at least two
different plasmid preparations and statistically analyzed using
Student's t-test. Results are presented as mean±S.E.M. ⁎pb0.05 is
considered statistically signiﬁcant.
3. Results
3.1. NRSF promotes opioid ligand-binding activity of endogenous MOR
and protein expression of MOR when NRSF localizes in cytoplasm
Previous studies on NRSF function [10,11] showed that over-
expressed NRSF increased the luciferase reporter activity of the MOR
promoter in some cells, although NRSF repressed its target transcript
(i.e., the MOR gene). This suggested that NRSF has a posttranscrip-
tional function in addition to its transcriptional repressor activity. Toverify whether NRSF expression led to enhance the MOR expression,
pMORGFP300 and either NRSF expression vector or only vector was
cotransfected to NMB cells. The expression of MOR–GFP fusion protein
was increased by NRSF expression (Fig. 1A). In addition, when the
myc-tagged NRSF expression plasmid was transfected transiently into
MOR-positive cells (Fig. 1B), the opioid ligand-binding activity of the
endogenous MOR increased about 2-fold in SHSY5Y cells and 5-fold in
NMB cells, compared to cells transfected with control vector (Fig. 1C).
However, NRSF apparently repressed MOR transcription, as conﬁrmed
by reverse transcription-PCR (RT-PCR) and real-time quantitative PCR
(RT-qPCR; Fig. 1D), consistent with the results from our previous
studies [10,11].
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neuronal gene in nonneuronal cells. Previous studies reported that the
promoter activity of constructs containing the NRSE sequence was
decreased by NRSF expression in NRSF-negative PC12 cells [10,21,32].
We carried out the following experiments to verify whether the
posttranscriptional activation of the MOR was mediated in a cell-
speciﬁc manner. TheMOR expression plasmid pMORNRSE (containing
the 5′ untranslated region of theMOR gene and the entireMOR coding
region; [28]) was cotransfected with either NRSF expression vector or
control vector into PC12 and NMB cells. Thirty hours after transfection,
we measured the speciﬁc binding activity of the MOR. The results
showed different functional responses in PC12 and NMB cells. In PC12Fig. 4. NRSF expression increases MOR/luciferase mRNA translation. (A) Formaldehyde gel e
system. (B) Luciferase activity of the in vitro-transcribed pNRSE300sp6 and pmNRSE300sp6 m
cells. PCRs were performed (RT+) or not (RT−) with MOR-speciﬁc primers and β-actin was us
activity of each construct is expressed as relative levels of luciferase activity. All values corres
versus mock vector transfection.cells, the opioid ligand-binding activity of MOR was decreased by
NRSF overexpression. In contrast, the ligand-binding was increased by
NRSF in NMB cells (Fig. 2A).
Recent studies reported that NRSF is expressed outside the
nucleus in embryonic stem cells and mouse brain cholinergic cells
[23, 33]. We carried out transient transfections of the NRSF
expression plasmid into PC12, NMB and hippocampal primary
neurons and determined NRSF localization by ﬂuorescence micro-
scopy and western blot. Surprisingly, the NRSF is expressed only in
the nucleus in PC12 cells but in both the nuclei and cytoplasm in
NMB cells and hippocampal primary neurons (Fig. 2B–D). This
suggests that when NRSF is in the nucleus, it functions asletrophoretic analysis of MOR/luciferase mRNA produced with an in vitro transcription
RNA. (C) The mRNA levels of pNRSE300sp6 and pmNRSE300sp6 from NMB-transfected
ed as an internal control. (D) Quantitative analyses of the blots in (C). (E) The promoter
pond to mean±S.E.M. calculated from at least three independent experiments. ⁎pb0.05
Fig. 5. NRSF binds to NRSE RNA sequences in vitro and in vivo. (A) Autoradiogram of the
NRSF and SOX21 protein translated by a coupled transcription/translation system in the
presence of [35S]-methionine. (B) RNA supershift assay performed using [35S]-
methionine-labeled NRSF. Lanes 2–7 contain samples from in vitro-translated myc-
tagged NRSF. Lane 1, probe (20 pmol) and reticulocyte (RRL); lane 2, probe (10 pmol);
lane 3, probe (5 pmol); lane 4, PU.1 probe (negative control, 20 pmol); lane 5, probe
(20 pmol) and nonspeciﬁc antibody (ﬂag); lane 6, probe (20 pmol) and preimmune
serum (PI); lane 7, probe (20 pmol) and myc antibody. (C) RNA EMSA. IVT: in vitro-
translatedmycNRSF protein. Lane 1, probe and RRL; lane 2, in vitro-translatedNRSF only;
lane 3, prove and IVT; lane 4, antisense probe (AS; 10 pmol) and IVT; lane 5, mutated
probe (mS; 10 pmol) and IVT; lane 6, probe and in vitro-translated SOX21 protein. (D)
RNA immunoprecipitation in NMB cells using a mouse monoclonal NRSF antibody.
ImmunoprecipitatedRNAwas analyzedby PCRusing twokinds of primers that ampliﬁed
188-bp and 730-bp, respectively, covering theNRSE of theMORgene. Lane 1,100-bpDNA
marker; lane 2, input; lane 3, immunoglobulin G; lane 4, 10 µg of mouse monoclonal
NRSF antibody; lane 5,10 µg of mousemonoclonal myc antibody (nonspeciﬁc antibody). Fig. 6. Translation of the MOR/luciferase transcript is promoted by the NRSF protein in
an in vitro translation system. Capped and uncapped MOR/luciferase mRNA transcripts
(100 ng) were translated in RRL with or without NRSF protein. (A) Relative levels of
luciferase activity. All values correspond to mean±S.E.M. calculated from at least three
independent experiments. ⁎pb0.05 versus no added NRSF protein. (B) Autoradiograms
of translation products from RRL were analyzed on a 3–8% SDS-PAGE gel.
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in the cytoplasm it has a novel function enhancing translational
regulation.3.2. The expression of NRSF enhances MOR promoter activity
Previous studies observed that overexpression of NRSF increased
the promoter activities of corticotrophin-releasing hormone and
dynamin I-and pax4-paired homeodomain genes [21,22,32]. However,
the mechanism by which NRSF increases these promoter activities
remains unknown, especially since NRSF exerted a repressive function
on the same genes at the transcriptional level. To determine whether
NRSF also activated MOR promoter activity, we introduced NRSF
expression plasmid with either wild-type (pNRSE450) or NRSE-
mutated (pmNRSE450) MOR/luciferase reporter constructs (Fig. 3A)
into NMB cells. Promoter activity was determined by measuring the
activity of the luciferase reporter. When the pNRSE450 construct was
cotransfected with the NRSF expression plasmid into NMB cells,
promoter activity increased about 7-fold relative to that of the cells
transfected with the control vector (Fig. 3C) without any change in the
level of transcriptional regulation (Fig. 3B). In contrast, the NRSF
expression plasmid only increased promoter activity 2-fold when
cotransfected with the mutant transcript. These data indicated that
the enhancement of pNRSE450 promoter activity in these cells was
mediated in a NRSE sequence-speciﬁc manner, resulting in a
promotion of the posttranscriptional, but not transcriptional, effects
of the NRSF protein.
To eliminate the transcriptional regulation effects, we generated
wild-type and mutated mRNA transcripts (pNRSE300sp6 and
pmNRSE300sp6, respectively) with an in vitro transcription system
(Fig. 4A). These in vitro-generated mRNAs were transfected into NMB
cells with either the NRSF expression plasmid or control vector. The
mere addition of amino acids to the luciferase protein produced by the
pNRSE300sp6 and pmNRSE300sp6 constructs did not itself affect
luciferase activity (Fig. 4B). However, cotransfection of NRSF markedly
increased the luciferase activity of pNRSE300sp6 mRNA relative to
control-transfected cells (Fig. 4E), without signiﬁcantly altering the
posttransfection transcript levels (Fig. 4C and D). These results suggest
that the enhancement of luciferase activity in neuronal NMB cell is
mediated by NRSF binding to the NRSE of the MOR transcript.
1843C.S. Kim et al. / Biochimica et Biophysica Acta 1783 (2008) 1835–18463.3. NRSF interacts with the NRSE sequence of MOR transcripts to
regulate MOR translation in vitro and in vivo
To determine whether NRSF interacts with the NRSE sequence of
MOR transcripts, we performed RNA supershift assays with [35S]-
methionine-labeled proteins generated from myc-tagged NRSF and
SOX21 plasmids (as a negative control) using an in vitro translation
system (Fig. 5A). In the electrophoretic mobility shift assay (EMSA),
the single-strandmRNA probe (from −18 to +24 of the MOR) formed a
complex with the NRSF protein increased depending on the mRNA
probe concentration (Fig. 5B, lanes 2 and 3), but not with PU.1 single-
strand mRNA probe as a negative control (Fig. 5B, lane 4). Moreover,
the supershift of the complex was observed when incubated with
anti-c-myc antibody, demonstrating the speciﬁc binding of NRSF to
the NRSE mRNA probe (Fig. 5B, lane 7). Incubation with the
nonspeciﬁc ﬂag antibody (as a negative control) or preimmune
serum Fig. 5B, lanes 5 and 6, respectively) had no effect on NRSF/RNA
complex formation. As an additional test of speciﬁc binding between
NRSF and NRSE mRNA (Fig. 5C), NRSF formed with only sense mRNA
prove (Fig. 5. lane 3) but antisense (AS) and mutated sense RNA probe
(mS) were not detected the binding complex with either in vitro-
translated NRSF (Fig. 5C, lanes 4 and 5) or SOX21 (negative control)
protein (Fig. 5C, lane 6).
To validate endogenous NRSF binding to MOR mRNA in vivo, we
carried out in vivo RNA immunoprecipitation (IP) assays. After cross-
linking the proteins and RNAs with formaldehyde, cell lysates from
NMB cells were subjected to immunoprecipitation with NRSF anti-
body, IgG and c-myc antibody (as a negative control). The precipitated
total RNAs were ampliﬁed by RT-PCR with two different speciﬁc
primers designed to generate a 188-bp fragment and a 730-bp
fragment, covering the NRSE in the MOR gene. RT-PCR-ampliﬁed IP
products were detected with NRSF antibody, but not IgG or c-mycFig. 7. NRSF can regulate eIF4G phosphorylation. (A) Overexpression of NRSF increases eIF
proteinwas extracted after 24, 30 or 48 h, followed bywestern blots probedwith antibodies a
Quantitative analysis of the blot in (A). (C) NMB cells were transfected with siRNAs targeting
(endo-NRSF) and eIF4G phosphorylation was monitored by western blot analysis usin
nonphosphorylated eIF4G. (D) Quantitative analyses of the western blots showed changes iantibody (Fig. 5D). Taken together, the results of the RNA immuno-
precipitation and EMSA studies demonstrate that NRSF interacts with
the NRSE element of the MOR mRNA.
3.4. Recombinant NRSF activates MOR translational regulation in RRL
To investigate the role of NRSF in translation mediated speciﬁcally
by the NRSE in the MOR transcript, we used the MNase-treated rabbit
reticulocyte lysate (RRL) as an in vitro translation system. Because RRL
does not contain any detectable levels of NRSF (data not shown), a
direct effect of NRSF on NRSE-mediated translation was assessed by
adding in vitro-translated NRSF protein to RRL (Fig. 6). The experi-
ments were performed with capped and non-capped MOR/luciferase
reporter mRNAs from an in vitro transcription system with either
NRSF protein or RRL alone (as a control). When the capped MOR/
luciferase mRNA was present in RRL, addition of the NRSF protein led
to an approximately 2-fold increase in luciferase activity relative to
control samples. In contrast, non-capped MOR/luciferase mRNA
detected no enhancement by the NRSF protein (Fig. 6A). SDS-PAGE
analysis conﬁrmed the increase of [35S]-methionine-labeled MOR/
luciferase protein induced by the addition of NRSF protein to the RRL
system (Fig. 6B).
3.5. Overexpression and knockdown of NRSF can control the
phosphorylation of eIF4G
In eukaryotic cells, translation processing consists of 3 steps:
initiation, elongation and termination. Initiation has been studied as a
critical step in gene expression. To explore whether NRSF affects
initiation of translation processing, we performed western blot
analysis after transfection of NRSF to examine the activation of
initiation factors. We observed that eIF4G phosphorylation was4G phosphorylation. NMB cells were transfected with myc-tagged NRSF plasmid and
gainst mycNRSF and both the phosphorylated and unphosphorylated forms of eIF4G. (B)
mRNA encoding NRSF (si-1 and si-2) or control siRNA (scb). Reduction of NRSF protein
g mouse monoclonal NRSF antibody and antibodies against phosphorylated and
n the level of phosphorylation, but not protein levels.
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NRSF expression (Fig. 7A and B). To conﬁrm these results, we used
siRNA to knock down endogenous NRSF in NMB cells. Two kinds of
siRNA duplexes targeting NRSF were transfected into NMB cells. After
48 h, cell lysates were collected and analyzed for endogenous NRSF
protein expression by western blot analysis. We observed a strong
reduction of NRSF protein levels in NMB cells transfected with the NRSF
siRNAs, but not in untransfected cells or in cells transfected with a
control siRNA (Fig. 7C and D). The overall levels of eIF4G were not
affected by NRSF siRNA or control siRNA transfection. However, the
siRNA-mediated knockdowns of NRSF led to a 5-fold decrease in the
phosphorylation of eIF4G. There was no effect on the phosphorylation of
eIF4G in untransfected or control siRNA transfected cells. Altogether,
these results demonstrate that NRSF is able to control eIF4G phosphor-
ylation, a putative translation initiation factor for the MOR gene.
3.6. NRSF enhances delivery of MOR/luciferase transcripts to the
polysome fraction, promoting translational regulation
To address whether NRSF enhanced translation in a NRSE-
sequence-speciﬁc manner, we examined the transcript levels in theFig. 8. NRSF increases transcript levels in the polyribosome fraction, and NRSF
localizes in the polyribosome fraction. NMB cells were cotransfected with pNRSE450
or pmNRSE450 and either vector or mycNRSF plasmid. The cells were resuspended in
a polysomal buffer and then pelleted by ultracentrifugation. The supernatant
provided the postpolysomal fraction. RNA was isolated from the polysomal fractions.
(A) Autoradiograms of RT-qPCR products. (B) Quantitative Realtime RT-PCR analysis
of total RNA from polysome fraction. All values correspond to mean±S.E.M. calculated
from at least three independent experiments. ⁎pb0.05 versus mock vector
transfection. (C) Western blots analysis performed by anti-myc, anti-NRSF and anti-
eIF4E (as a protein loading control).polysome fraction by RT-qPCR. The pNRSE450 and pmNRSE450
constructs were cotransfected into NMB cells with either NRSF
expression plasmid or control vector. After 30 h, MOR/luciferase
transcripts were isolated from both whole cells and the polysome
fraction as total and polysomal RNA, respectively (Fig. 8A). The
isolated RNAs were subjected to quantiﬁcation of transcripts followed
by real-time quantitative PCR (RT-qPCR) with speciﬁc primers.
Transcription levels were increased in the polysomal RNA when the
pNRSE450 was cotransfected with the NRSF expression plasmid, but
not with the control vector (Fig. 8A and B). In contrast, total RNA
transcripts of pNRSE450 were not affected by NRSF expression.
Likewise, neither total RNA nor polysomal levels of the mutated
NRSE construct were changed by contransfection of NRSF (Fig. 8A and
B). These results show that NRSFmay interact with the NRSE sequence
of the MOR/luciferase transcript and promote localization of the
transcripts to the ribosome complex, resulting in enhanced transla-
tion. To support this hypothesis, we assayed for the presence of NRSF
in the polysome fraction. As predicted, western blots using mono-
clonal NRSF antibody and c-myc antibody for NRSF protein detected
NRSF protein in the polysome extract of cells transfected with NRSF
expression plasmid detected by but not in extracts from cells
transfected with vector only (Fig. 8C). The eIF4E was used as protein
loading control.
4. Discussion
The mu opioid receptor serves as the principle physiological
target for most clinically important opioid analgesics, including
those with high addiction liability such as morphine and fentanyl
[34]. To better understand the factors regulating MOR expression,
we have studied the regulatory regions of its gene and examined
the function of transcription factors in MOR gene regulation [4,5,7–
15,30,34]. Previous studies showed that NRSF is an important
transcriptional regulator of MOR gene expression [10,11,35]. In vivo,
NRSF is expressed widely throughout the ventricular neuroepithe-
lium [36] and is present in many adult cortical neurons [37]. In the
hippocampus, most neurons of the pyramidal and granular layers
express NRSF [23].
Originally, NRSF was identiﬁed as a repressor that silenced the
neuronal gene in nonneuronal cells via binding to the neuron-
restrictive silencer element [10,11,32,37–47]. It has also been reported
to function as a tumor repressor mediating the PI(3)K signaling
pathway [18], although its exact mechanism of action in this regard
remains to be determined. While several reports claimed that in
neuronal cell lines, NRSF/NRSE had no regulatory function [46,48,49],
other studies observed that NRSF/NRSE could either increase or
decrease expression of its target gene depending on the temporal or
spatial context in which the gene was expressed [20–22]. In addition,
it should be noted that overexpression of the dominant-negative NRSF
and knockout of NRSF failed to release the repression of its gene
completely, even though NRSF was originally found as a repressor
[50]. One study in particular reported that a NRSE in the neuronal
nicotinic acetylcholine receptor 2-subunit gene may either silence or
enhance transcription, depending on the cellular context within the
nervous system in transgenic mice [19]. In neuronal cells in vitro, NRSE
activates transcription of synthetic promoters when located down-
stream of the 5′-untranslated region or at less than 50 bp upstream
from the TATA box. However, it switches to a silencer when located
further upstream. In contrast, in nonneuronal cells, NRSE always
functions as a silencer. Antisense RNA inhibition shows that the NRSE-
binding protein NRSF contributes to the activation of transcription in
neuronal cells [19]. Similarly, in adult neural stem cells, NRSE dsRNA
interacted with NRSF resulting in expression of neuronal gene and cell
differentiation [51].
In the present study, overexpression of NRSF in SHSY5Y and
NMB cells increased endogenous MOR ligand-binding activity
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cells express high levels of MOR despite strong endogenous
expression of NRSF. Furthermore, MOR ligand-binding activity was
increased in NMB cells cotransfected with MOR and NRSF. In
contrast, NRSF expression signiﬁcantly decreased binding activity
in PC12 cells. This suggests that NRSF may have a function in
these cell lines other than that of a transcription repressor. One
possible mechanism that could account for this is that MOR NRSE
also acts as an activator in certain cell lines. However, in our
study, transcription levels both in vitro and in vivo were not
increased signiﬁcantly by transfection of the NRSF expression
plasmid. On the other hand, cotransfection of a NRSF expression
plasmid with a MOR/luciferase construct containing a NRSE
sequence signiﬁcantly increased MOR/luciferase activity relative to
cells cotransfected with a mutated (e.g., NRSE-deﬁcient) MOR–
luciferase construct. This suggests that NRSF might be involved in
up-regulation of MOR expression through posttranscriptional or
translational regulation. Recently, one of breakthrough ﬁnding is
that NRSF interacts with and is inactivated by huntingtin, with
Huntington's disease mutation abrogating this interaction [52]. The
differences of NRSF localization in PC12 cell and NMB cells may
involve in huntingtin protein activity in neuron. This suggestion
remains as further study for explanation of NRSF function in out of
nucleus.
We hypothesized that NRSF is involved in translational regula-
tion depending on its localization in neuronal cells. In PC12 cells,
NRSF is expressed mainly in the nucleus, but it is expressed in both
the nucleus and cytoplasm of hippocampal neurons and NMB cells.
Furthermore, NRSF up-regulates the cap-dependent translation of
NRSE-containing mRNA and enhances eIF4G phosphorylation in
NMB cells. Phosphorylation of eIF4G on residues in its COOH-
terminal (including Ser1108) fully activate eIF4G [53], and increased
phosphorylation of eIF4G on Ser1108 is associated with enhanced
formation of active eIF4G/eIF4E complexes in cells [53,54], leading
to an increased rate of protein synthesis. Likewise, elevated
phosphorylation of eIF4G correlates with mRNA translation in
skeletal muscle during perfusion of the hindlimb with buffer
containing leucine [3] or following oral administration of a single
bolus of leucine [55].
In the present study, RNA gel-shift assays and RNA immuno-
precipitation revealed that NRSF bound to the NRSE region of MOR
transcripts. Furthermore, transfection with NRSF expression plas-
mids caused increased localization of MOR/luciferase transcripts to
the polysomal fraction, and NRSF was expressed in the polysomal
compartment of fractionated cells. Finally, overexpression of NRSF
enhanced the phosphorylation of eIF4G, while NRSF knockdown by
siRNA signiﬁcantly decreased phosphorylation. Taken together,
these data suggest a possible novel mechanism for NRSF in
addition to its role as a transcriptional regulator: bound NRSF is
translocated from the nucleus in certain cell types when MOR
mRNA is transported to the ribosomal complex for translation.
Once there, phosphorylation of eIF4G by NRSF enhances formation
of the eIF4G/eIF4E complex, resulting in translational activation.
Although a number of studies have reported that NRSF acts as a
transcriptional repressor of over 30 genes and established its
mechanism of action, several unsolved issues remain. Why is NRSF
expressed in so many neuronal cell types and in mature neurons in
brain?Why does it have no apparent function in some cells types? Can
NRSF also function as a transcriptional activator? Why are NRSF
knockouts unable to fully release its control of gene expression? In this
study, we demonstrate one possible function for NRSF in some
neuronal cells, not as a transcriptional factor but as a translational
activator. This novel function and mechanism may provide an insight
into the complexity of the regulatory systems involved in the
variations of gene expression in different regions of the central
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